ATCC ATCC Logo 0
  • Quick Order
  • Resources
  • Support

2022 News Releases

CAR-T cells, CAR-Target, CD19, CD20, HER2 November 03, 2022

ATCC Announces New Immuno-oncology CAR-T Target Luciferase Reporter Cell Lines to Enable Discovery and Development of Immunotherapies

ATCC announced a new line of products, CAR-T Target luciferase reporter cell lines, that will support immuno-oncology (IO) discovery and development of novel immunotherapies.

Fluorescent green, blue, and red prostate cancer organoid xenograft. August 23, 2022

ATCC Announces New Award from NCI to Process Biomaterials for Cancer Research

ATCC announced that is has received an award by the NCI to collect, process, and manage biological specimens for use in long-term epidemiology cancer research studies for the DCEG Field and Biospecimen Support Services program.

New ATCC building entrance. July 12, 2022

ATCC Expands Leadership Team to Provide Vision and Growth Strategy

ATCC announces that it has made two key promotions within its leadership team.

Red sphere inside the transparent Leishmaniasis parasite with a tail. June 13, 2022

ATCC Awarded Two Contracts from Gennova Biopharmaceuticals for the Continued Development of Cell Banks to Help Diagnose and Prevent Leishmaniasis

ATCC announced that it has been awarded two contracts from Gennova Biopharmaceuticals Limited to continue its work with the biotechnology company on a diagnostic test and vaccine for Leishmaniasis.

Strands of blue and white-beaded DNA double helixes floating in the air upright, with a woman in a lab coat touching a strand and light illuminating it. April 12, 2022

ATCC Announces Two Projects from the US Department of Agriculture

ATCC Announces Two Projects from the U.S. Department of Agriculture’s Chief Scientific In-House Research Agency, the Agricultural Research Service

New ATCC building entrance. April 04, 2022

ATCC Announces Expansion of its Bioinformatics Data Platform with QIAGEN

ATCC announced that it has entered into an agreement with QIAGEN to provide them with sequencing data from its collection of cell lines to be included in QIAGEN’s databases for biotechnology and pharmaceutical companies for research purposes.

New ATCC building entrance at dusk with lights. March 28, 2022

ATCC Announces Award from NCI to Provide Cancer Epidemiology Services to the Research Community

ATCC received a task order contract, with a ceiling value of $5.6 million from NCI to receive, process, store, analyze, and distribute clinical specimens related to different cancer types.

Exterior of new ATCC building. March 14, 2022

ATCC Announces Award from NIAID to Develop Well-characterized Challenge Material

ATCC received a task order contract, with a ceiling value of $1.9 million from NIAID to develop well-characterized challenge material (WCCM) for therapeutic development.

New ATCC building entrance. February 15, 2022

ATCC Announces Awards from DTRA that Strengthen ATCC's Antiviral Drug Discovery

ATCC has been awarded three grants valued at over $5.5 million by the Defense Threat Reduction Agency (DTRA) to identify and characterize novel therapeutic approaches to viruses of global health concern.

New ATCC building entrance at night with lights. February 10, 2022

ATCC Announces Award from CDC for DNA Plating and Storage Services

ATCC has been awarded a five-year, Indefinite Delivery/Indefinite Quantity (IDIQ) contract by the CDC to support the National Health and Nutrition Examination Survey (NHANES).

Green and blue conditionally reprogrammed organoid cells. January 06, 2022

ATCC Announces Award from Leidos Biomedical Research for the Production and Distribution of Next-generation Cancer Models

ATCC announced that it has been awarded a contract with Leidos Biomedical Research for the continued production, characterization, and distribution of next-generation cancer models (NGCM).